DDInter1152 DDInter1233
Mephenytoin is used for the treatment of refractory partial epilepsy. Mephenytoin is a solid. This compound belongs to the phenylhydantoins. These are heterocyclic aromatic compounds containing an imiazolidinedione moiety substituted by a phenyl group. Mephenytoin is known to target sodium channel protein type 5 subunit alpha. Cytochrome P450 2C19, Cytochrome P450 2C8, Cytochrome P450 2C9, Cytochrome P450 2B6, Cytochrome P450 1A2, and Cytochrome P450 2D6 are known to metabolize mephenytoin. Mephenytoin is a hydantoin-derivative anticonvulsant used to control various partial seizures. Mephenytoin and oxazolidinedione derivatives are associated with higher incid
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Chlorcyclizine
Chlorcyclizine {u} (Compound) resembles {v} (Compound) Mitotane
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) downregulates {v} (Gene) NVL
NVL {u} (Gene) is downregulated by {v} (Compound) Mitotane
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) Mitotane
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Carbinoxamine
Carbinoxamine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) Mitotane
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is downregulated by {v} (Compound) Mitotane
Mephenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chlorpheniramine
Chlorpheniramine {u} (Compound) resembles {v} (Compound) Chlorcyclizine
Chlorcyclizine {u} (Compound) resembles {v} (Compound) Mitotane
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Esomeprazole
Esomeprazole {u} (Compound) causes {v} (Side Effect) Connective tissue disorder
Connective tissue disorder {u} (Side Effect) is caused by {v} (Compound) Mitotane
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Bortezomib {u} (Compound) downregulates {v} (Gene) ADGRE5
ADGRE5 {u} (Gene) is upregulated by {v} (Compound) Mitotane
Mephenytoin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) causes {v} (Side Effect) Rash
Rash {u} (Side Effect) is caused by {v} (Compound) Mitotane
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Mitotane (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) downregulates NVL (Gene) and NVL (Gene) is downregulated by Mitotane (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Carbinoxamine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Mitotane (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine (Compound) resembles Chlorpheniramine (Compound) and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Mitotane (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is downregulated by Mitotane (Compound)
Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Mitotane (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Esomeprazole and Esomeprazole (Compound) causes Connective tissue disorder (Side Effect) and Connective tissue disorder (Side Effect) is caused by Mitotane (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib (Compound) downregulates ADGRE5 (Gene) and ADGRE5 (Gene) is upregulated by Mitotane (Compound)
Mephenytoin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Mitotane (Compound)